|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Adprotech Ltd., of Cambridge, UK, received from European regulatory authorities orphan drug designation for APT070, designed to prevent graft dysfunction in kidney transplantation. The candidate is scheduled to enter Phase II trials during the fourth quarter. It also is in Phase II studies to treat rheumatoid arthritis.
AlphaRx Inc., of Richmond Hill, Ontario, said recently compiled data and results on ARX2002, a nonsteroidal compound, demonstrate anti-inflammatory activity at least 20 times greater than Indomethacin, a nonsteroidal anti-inflammatory drug. ARX2002 and AlphaRx's other lead compound, ARX2001, are being tested in more advanced neuroprotective models ...
Related newspaper, magazine, and journal articles:
|
|
Article: Dr. Ivor Royston Joins Forward Ventures as ...
Business Wire;
June 14, 2001 ;
700+ words
... ... Royston, M.D., has joined the Forward Ventures management team full-time, following ... has served as a managing member of Forward Ventures, a life sciences and health care ... treatments," said Royston. "With Forward Ventures, I'm heading in a new direction ...
|
|